Skip to main content

Table 1 General characteristics of the study participants

From: Immunosenescence of the CD8+ T cell compartment is associated with HIV-infection, but only weakly reflects age-related processes of adipose tissue, metabolism, and muscle in antiretroviral therapy-treated HIV-infected patients and controls

  Controls HIV+
  N = 10 N = 43
  Median or n IQR or % Median or n IQR or %
Demography and lifestyle     
 Age (years) 48.1 41.9–62.3 49.8 43.3–55.2
 Smoking 0 0 % 14* 32.6 %
Body composition     
 Lipodystrophy 14 32.6 %
 BMI (kg/m2) 25.4 24.7–28.6 25.1 23.0–27.7
 FMI (kg/m2) 5.2 4.6–7.5 4.6 3.4–6.4
 VAT (cm2) 111.6 93.5–157.5 150.8 115.0–212.2
lLMI (kg/m2) 6.4 6.2–6.8 6.1 5.7–6.6
Metabolic parameters     
 HOMA-IR 0.5 0.5–1.3 1.2* 0.6–2.4
 Metabolic syndrome 1 10 % 20 46.5 %
Biomarkers of inflammation     
 IL-6 (pg/mL) 1.1 0.7–2.4 1.6 1.1–2.6
 suPAR (ng/mL) 1.8 1.5–2.1 2.2* 1.8–2.8
HIV- and immune-related parameters     
 HIV duration (years) 14 6.6–21.0
 ART duration (years) 10.2 4.4–14.8
 Current PI treatment 13 30.2 %
 Current NRTI treatment 43 100 %
 Current NNRTI treatment 28 65.1 %
 Other current ART 4 9.30 %
 HIV RNA ≤20 copies/mL 39 90.7 %
 CD4+ T cell count (cells/μL) 729 674–880 580 403–820
 CD8+ T cell count (cells/μL) 373 281–440 828*** 618–1120
 CD4:CD8 ratio 2.0 1.8–3.0 0.7*** 0.5–1.0
  1. Continuous measures are listed as: median and interquartile range. Categorical variables are listed as: number of participants and percentage
  2. Abbreviations: BMI body mass index, ART antiretroviral therapy, FMI fat mass index, HOMA-IR homeostatic model assessment of insulin resistance, IL-6 interleukin-6, IQR interquartile range, lLMI leg lean mass index, NRTI nucleoside reverse-transcriptase inhibitors, NNRTI non-nucleoside reverse-transcriptase inhibitor, PI protease inhibitor, suPAR soluble urokinase plasminogen activator receptor, VAT visceral adipose tissue
  3. The bold values are statistically significant at * P < 0.05, ** P < 0.01, *** P < 0.001